Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tercica: Growing Small

This article was originally published in Start Up

Executive Summary

Armed with a powerful, in-licensed late-stage molecule from Genentech, two-and-a half-year-old Tercica is about a year away from entering the eminently reachable market for treating short-stature children, a potentially significant segment of a $750 million annual US market. But unlike many start-up in-licensers that seek niche indications for their lead programs, Tercica won't be able to fly under the radar of the competition.

You may also be interested in...



For the Moment, Pharmion Helps Burnish Biotech's Image

Biotech's unique volatility and the intuition that risk will be rewarded when science and business manage to click for the benefit of patients are also powerful incentives--including for drugs that fall under Pharma's radar. That dynamic seems to be playing out for the moment for Pharmion--the rare standout in the score of recent biopharm IPOs--as it prepares to roll out its recently approved drug, Vidaza.

Starting in the Marketplace

InterMune spun out of Connetics three years ago to develop many small infectious disease indications for interferon gamma (Actimmune), which Genentech had virtually abandoned. Soon after InterMune was established, it received a pleasant surprise when Actimmune showed activity in idiopathic pulmonary fibrosis. That unexpected blockbuster market opportunity accelerated its growth, enabling the company to go public and raise over $450 million with which to expand its resources and clinical programs. With Actimmune as a model, InterMune has been able to in-license three other marketed and late-stage products. Now it wants to add preclinical or IND compounds to its portfolio. However, taking on early-stage risk to be able to capture a greater share of the upside of a drug puts the company in the same arena as many other in-licensors, one where its clinical and medical marketing expertise are less critical skill sets. Phase III data on Actimmune in IPF are expected in November. An early commercial success in this disease could make InterMune a player in M&A.

Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel